Oppenheimer Maintains Outperform on RxSight, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on RxSight (NASDAQ:RXST) but lowers the price target from $72 to $65.
August 06, 2024 | 11:59 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on RxSight but lowers the price target from $72 to $65.
The Outperform rating suggests continued confidence in RxSight's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100